Twist Bioscience

TWST

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding

In their latest 13F (Q3 2026)

See who

Value held

$5.7m

Combined value at quarter end

Last quarter

1 bought

0 sold or trimmed

Price at Q2 ’26 end

$102.88

+116.5% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

+116.5%Q2 ’26

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

0Q4 ’23

0Q1 ’24

0Q2 ’24

0Q3 ’24

0Q4 ’24

0Q1 ’25

0Q2 ’25

0Q3 ’25

0Q4 ’25

1Q1 ’26

1Q2 ’26

0Q3 ’26

Counts the managers on this site whose 13F for that quarter includes Twist Bioscience.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Twist Bioscience

Polen Capital Management	0.1%$5.7m	$5.7m	Added +130%	2 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works

From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.

Sort by

Insider purchases and sales of Twist Bioscience
		Bought or sold				Filing
9 Oct 2026	Laponis AdamChief Financial Officer	▼ Sold	2,462	$156.30	$385k	Form 4
5 Oct 2026	Leproust Emily M.Chief Executive Officer	▼ Sold	1,840	$200.44	$369k	Form 4
5 Oct 2026	Leproust Emily M.Chief Executive Officer	▼ Sold	1,017	$202.32	$206k	Form 4
5 Oct 2026	Leproust Emily M.Chief Executive Officer	▼ Sold	481	$201.26	$97k	Form 4
5 Oct 2026	Leproust Emily M.Chief Executive Officer	▼ Sold	432	$203.61	$88k	Form 4
5 Oct 2026	Leproust Emily M.Chief Executive Officer	▼ Sold	297	$205.78	$61k	Form 4
5 Oct 2026	Leproust Emily M.Chief Executive Officer	▼ Sold	290	$204.80	$59k	Form 4
5 Oct 2026	Leproust Emily M.Chief Executive Officer	▼ Sold	146	$206.84	$30k	Form 4
5 Oct 2026	Leproust Emily M.Chief Executive Officer	▼ Sold	45	$207.46	$9k	Form 4
2 Oct 2026	Leproust Emily M.Chief Executive Officer	▼ Sold	45,736	$188.88	$8.6m	Form 4
2 Oct 2026	Finn Patrick JohnPresident and COO	▼ Sold	25,714	$188.88	$4.9m	Form 4
2 Oct 2026	Green PaulaSVP of Human Resources	▼ Sold	10,088	$188.88	$1.9m	Form 4
2 Oct 2026	Cho DennisSee Remarks	▼ Sold	9,514	$188.88	$1.8m	Form 4
2 Oct 2026	Laponis AdamChief Financial Officer	▼ Sold	8,057	$188.88	$1.5m	Form 4
2 Oct 2026	Werner Robert F.Chief Accounting Officer	▼ Sold	1,482	$188.88	$280k	Form 4
1 Oct 2026	Leproust Emily M.Chief Executive Officer	▼ Sold	655	$200.00	$131k	Form 4
24 Sep 2026	Leproust Emily M.Chief Executive Officer	▼ Sold	2,485	$175.23	$435k	Form 4
24 Sep 2026	Leproust Emily M.Chief Executive Officer	▼ Sold	945	$176.39	$167k	Form 4
24 Sep 2026	Leproust Emily M.Chief Executive Officer	▼ Sold	515	$180.39	$93k	Form 4
24 Sep 2026	Leproust Emily M.Chief Executive Officer	▼ Sold	501	$183.76	$92k	Form 4

About the company

Sector: Health care · Biological Products, (No Diagnostic Substances)
Incorporated in: Delaware
Financial year ends: 30 September
Shares outstanding: 63m at 29 Jul 2026
SEC filings: Annual reports and other filings on EDGAR

Revenue and profit

Twist Bioscience revenue and net income by year
Year	Revenue	Net income
Year to Sep 2025	–	−$77.7m
Year to Sep 2024	–	−$209m
Year to Sep 2023	–	−$205m
Year to Sep 2022	–	−$218m
Year to Sep 2021	–	−$152m
Year to Sep 2020	–	−$140m
Year to Sep 2019	–	−$108m
Year to Sep 2018	–	−$71.2m
Year to Sep 2017	–	−$59.3m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.